Lytix Biopharma AS (OSL:LYTIX) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:LYTIX Lytix Biopharma AS OSL:LYTIX
28 GF Score
Price kr8.74
GF Value kr0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

OSL:LYTIX
28GF Score
Lytix Biopharma AS OSL:LYTIX
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of kr8.74 is trading 5041.2% above its estimated GF Value™ of kr0.17. GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.

Key valuation signals for OSL:LYTIX:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr0.17 vs. price of kr8.74 (5041.2% above fair value)
  • GF Score™: 28/100 with 2 warning signs

No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
28GF Score

Get the complete analysis for OSL:LYTIX

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.74
Price
kr0.17
GF Value